May I second tortuga-soup's recommendation that you folks check out VICL. Vical has developed and patented a non-viral DNA vaccine delivery method that is currently in late stage development on a variety of vaccines with MANY big name partners in the drug sector, most notably Merck. The importance of Vical is that they're selling a revolutionary METHODOLOGY wich is well on the way to proving itself as the basis for development of a multitude of Vaccines including Cancer.
IMO the highest endorsement of all has come from the NIH (National Institute for Health) who has just licensed Vical's "Naked DNA Vaccine Technology" for an initial royalty payment of 7 Million dollars in the first of what will be many such payments.(see link at bottom of page) Their technology will be presented at the Roth Capital symposium at 12:30 Pacific time on Tuesday which will be webcast live: http://biz.yahoo.com/prnews/040211/law099_1.html
Vaccines waiting for approval or currently under development using Vicals patented technology:
HIV HEPATITUS A,B and C EBOLA ANTHRAX WEST NILE MELANOMA SMALL POX
*VICAL HAS A VERY STRONG BALANCE SHEET WITH A STRONG CASH POSITION.
*MUCH OF VICALS CURRENT MANAGEMENT WAS RECRUITED FROM MERCK AND THEY MAINTAIN A STRONG CO-DEVELOPMENT ALLIANCE WITH THEM.
The current prospects for approval on a blockbuster drug (including a HIV Vaccine) are high with Merck, but as this possiblity becomes stronger, the possibilty of a Merck (or rival) buyout becomes ever more likely. Merck is currently attempting to bolster their product pipeline with variety of partners, VICAL being the most significant IMO.
I feel VERY VERY good about the prospects over at VICL or I wouldnt mention it here. As always, I put my money where my mouth is. Full disclosure; I own 5000 shares.
They do own!> CEO just "acquired" 50,000 shares 4 days ago, on the same day as the NIH licensing revenue was announced. Notice that his shares were issued at a practically nil cost (.01), a common pracice in boardrooms that wish to reward CEO's for a job well done. Also note that in the latest quarter a net 245,000 shares were purchased overall. There are only 20 million shares outstanding so the massive dilution we've seen in stocks like SIRI and EAG are non issues.